An observational study in Esophageal Cancer, sponsored by Anyang Tumor Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Anyang Tumor Hospital · Observational
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Anyang Tumor Hospital is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced esophageal cancer
Exclusion Criteria:
None
This is an observational study
OS
Overall Survival
Time frame: From date of admission until the date of death from any cause, assessed up to 24 months
PFS
Progression Free Survival
Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anyang Tumor Hospital